Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine (692342) [GSK 692342] in HIV-Positive Adults.
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2017
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 19 Jul 2009 Results were presented at the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment (IAS 2009) held in Cape Town, South Africa.
- 10 Jun 2009 Actual patient number (37) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History